Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas
Abstract: Member company, Curtana Pharmaceuticals, announced that the FDA has granted orphan drug status to CT-179, the company’s lead Olig2 inhibitor. CT-179 is being developed to treat gliomas, including glioblastoma in adults and children. Source: PRLog
Read the press release here.